Credit Suisse Ag Biomarin Pharmaceutical Inc Call Options Transaction History

Credit Suisse Ag

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $609,620 - $777,495	-8,500 Reduced 7.28%	108,300 $9.57 Million
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $1.38 Million - $1.57 Million	-18,400 Reduced 13.61%	116,800 $9.03 Million
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $6.27 Million - $7.05 Million	-83,100 Reduced 38.07%	135,200 $11.3 Million
Q1 2021 May 14, 2021	BUY	$74.73 - $90.69 $1.34 Million - $1.62 Million	17,900 Added 8.93%	218,300 $16.5 Million
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $9.13 Million - $11.3 Million	125,700 Added 168.27%	200,400 $17.6 Million
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $5.37 Million - $9.79 Million	74,700 New	74,700 $5.68 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.